What's Driving Natera's Recent Stock Action
Natera (NTRA) has shown robust operational performance, exceeding Q4 2025 earnings and revenue expectations due to strong growth in its genetic testing portfolio. Despite strong fundamentals and a "Buy" consensus from Wall Street analysts, Natera has experienced a significant pattern of insider selling, totaling over $85.96 million in the last three months. This article explores the implications of this insider selling alongside the company's strong financial performance and market outlook.
Is It Time To Reconsider Natera (NTRA) After Its Strong Five Year Share Price Gain
This article analyzes Natera (NTRA) after its significant five-year share price gain, assessing whether its current valuation of US$203.69 is justified. Using a Discounted Cash Flow (DCF) model, the analysis suggests NTRA is undervalued by 33.3%, with an intrinsic value of US$305.18 per share. However, a Price to Sales (P/S) ratio comparison indicates it might be overvalued relative to Simply Wall St’s proprietary Fair Ratio.
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
Natera, Inc. will present 35 studies at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing its leadership in oncology data with findings on molecular residual disease (MRD) testing and other innovations. The presentations will highlight Natera's Treatment on MRD (TOMR) approach, the broad utility of Signatera as a pan-cancer tool, and the robust performance of its ultrasensitive phased variant technology. These studies aim to reinforce Signatera’s clinical utility and advance precision MRD-guided cancer care.
Natera Expands Operations in Austin
Natera, a global leader in cell-free DNA testing, is expanding its operations in Austin, Texas. This expansion includes opening a new laboratory and office facility, which will create hundreds of new jobs in the area. The move aims to increase Natera's capacity for processing critical diagnostic tests and support its continued growth.
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
Natera, Inc. (NASDAQ: NTRA) is significantly expanding its operations in Austin, Texas, by opening a second facility and additional lab space, which is expected to house the world's largest sequencing capacity. This expansion aims to meet increasing demand for its testing solutions, particularly in oncology, where volumes grew over 54% in Q1 2026. The company also anticipates creating up to 400 new jobs across various roles.
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling?
Natera (NTRA) recently reported a strong Q4 2025 earnings beat and optimistic 2026 revenue guidance, but co-founder Jonathan Sheena's stock sales, while pre-planned, contribute to a broader pattern of significant insider selling totaling $85.96 million. The company's impressive growth and improving gross margins are contrasted by persistent net losses and a high valuation. Investors face a complicated risk-reward profile, needing to weigh strong operational performance against insider movements and the journey to profitability.
Study of prenatal gene risk test now passes 2,000 patients
Natera's EXPAND clinical trial for its Fetal Focus single-gene noninvasive prenatal test (NIPT) has now enrolled over 2,000 patients, more than doubling its enrollment in the past year. The trial, which was recently featured at the SMFM Annual Meeting, assesses fetal risk for 21 genes linked to serious medical conditions. This milestone reinforces Natera's commitment to generating high-quality data for clinicians and families using their advanced cell-free DNA testing technology.
FDA Nod For Signatera MRD Blood Test Might Change The Case For Investing In Natera (NTRA)
Natera, Inc. (NTRA) recently received FDA approval for its Signatera CDx blood test, marking it as the first blood-based minimal residual disease companion diagnostic for guiding immunotherapy decisions in muscle-invasive bladder cancer. This approval validates MRD testing as a clinical decision tool and could strengthen Natera's oncology narrative, driving increased revenue expectations. However, investors should also consider the company's continued high spending, leading to ongoing losses, and growing legal/regulatory pressures despite the clinical win.
What's Behind Natera CEO Steven Chapman's Recent Stock Sales
Natera CEO Steven Chapman recently sold $1.15 million in company stock under a pre-arranged 10b5-1 plan, part of a consistent pattern of insider sales. Despite these dispositions, Natera reported strong Q4 2025 results, exceeding revenue and EPS estimates, fueled by high test volumes and growth in its oncology platform. The company's 2026 revenue guidance of $2.62 billion to $2.70 billion and positive cash flow outlook indicate continued operational strength, though profitability remains a long-term objective.
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
Natera, Inc. (NTRA) announced that its Signatera CDx received FDA approval as a companion diagnostic for adjuvant atezolizumab immunotherapy in patients with muscle-invasive bladder cancer (MIBC). This marks the first companion diagnostic approval in blood-based minimal residual disease (MRD) testing and is expected to significantly advance personalized oncology care. The approval is supported by positive findings from the Phase III IMvigor011 trial, which demonstrated improved outcomes for MRD-positive patients and the potential for personalized treatment decisions for MRD-negative patients.
Natera wins FDA approval for companion diagnostic
Natera has secured FDA approval for its blood-based molecular residual disease test, Signatera CDx, as a companion diagnostic. This test will help physicians identify muscle-invasive bladder cancer patients post-surgery who would benefit from Genentech’s immunotherapy Tecentriq, and conversely, those who may avoid unnecessary treatment. The approval highlights the growing role of MRD testing in guiding personalized cancer treatment and potentially reducing healthcare costs.
A Look At Natera (NTRA) Valuation After Recent Share Price Weakness
Natera (NTRA) has seen recent share price weakness, with a 10.6% drop over the past month, despite strong multi-year total returns and 14.8% revenue growth. The stock is currently trading at a roughly 39% discount to an intrinsic estimate of $259.11, suggesting it may be undervalued. This valuation is based on assumptions of ambitious growth, profitability improvements through new product launches, and personalized medicine trends, while acknowledging risks like clinical trial setbacks and high R&D costs.
Natera, Inc. (NTRA) Investor Outlook: Exploring A 39.99% Upside With Strong Buy Ratings
Natera, Inc. (NTRA), a key player in healthcare diagnostics with a $26.69 billion market cap, shows strong long-term growth prospects despite current losses. Analysts project a potential upside of nearly 40% with an average target price of $260.89, supported by impressive revenue growth of 38.80% and overwhelmingly positive analyst sentiment. The company, known for its innovative molecular testing services, is heavily investing in future growth with 17 buy ratings and no sell ratings.
Natera, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman
Wolf Haldenstein Adler Freeman & Herz LLP has announced that a securities class action lawsuit has been filed against Natera, Inc. (NAS:NTRA) in the United States District Court for the Western District of Texas. The lawsuit was publicly announced via PRNewswire on May 16, 2022. This alert provides notice of the ongoing legal action against the medical diagnostics and research company.
Natera Inc stock (US6323071042): insider selling and a sharp pullback unsettle investors
Natera Inc. experienced a stock price drop of over 5% following insider selling by co-founder Jonathan Sheena and a broader market pullback in high-growth diagnostics. Despite strong revenue growth in its molecular diagnostics business, particularly in oncology and organ health testing, the company continues to report net losses due to ongoing investments. The insider selling, though a relatively small portion of Sheena's holdings and conducted via a pre-arranged plan, contributed to short-term cautious sentiment among investors, compounded by negative technical signals.
New blood test helps tailor bladder cancer treatment, wins FDA backing
Natera's Signatera CDx, a personalized molecular residual disease (MRD) test, has received FDA approval as a companion diagnostic for adjuvant atezolizumab immunotherapy in muscle-invasive bladder cancer (MIBC). This approval marks a significant advancement in personalized cancer care, allowing treatment decisions to be guided by a patient's MRD status. The IMvigor011 trial showed that MRD-positive patients treated with immunotherapy had improved disease-free and overall survival, while MRD-negative patients achieved high 2-year overall survival without additional adjuvant therapy.
Natera (NTRA) co-founder Jonathan Sheena sells 4,650 shares under 10b5-1 plans
Jonathan Sheena, co-founder and director of Natera (NTRA), sold a total of 4,650 shares of common stock through pre-arranged Rule 10b5-1 trading plans. The sales, executed between approximately $199 and $210.345 per share, included both direct holdings and shares held indirectly through two trusts, marking a minor portion of his overall reported stake. Following these transactions, Sheena's directly held stake in Natera stands at 255,452 shares.
Natera co-founder Sheena Jonathan sells $959,450 in company stock
Natera co-founder and director Sheena Jonathan sold approximately $959,450 worth of company common stock through direct and indirect transactions on May 8 and May 13, 2026. These sales were conducted under Rule 10b5-1 trading plans, with individual share prices ranging from $199.4346 to $210.345. Despite Natera's strong revenue growth, analysts are divided on its near-term profitability, and InvestingPro tips highlight the stock's volatility and unlikelihood of profitability this year.
Natera (NasdaqGS:NTRA) Stock Forecast & Analyst Predictions
Natera (NTRA) is projected to grow earnings by 62.4% and revenue by 14.8% annually, with EPS expected to increase by 62.8% per year. Recent developments include FDA approval for Signatera CDx in bladder cancer, positive Q1 2026 revenue exceeding expectations despite wider net losses due to significant R&D and expansion investments. Several insider selling activities have been noted, though analysts generally maintain positive ratings with varying price targets, emphasizing Natera's molecular residual disease leadership and expanding diagnostic portfolio.
Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
Natera, Inc. announced that the FDA has approved its Signatera CDx as a companion diagnostic for adjuvant atezolizumab immunotherapy in muscle-invasive bladder cancer (MIBC). This marks the first FDA approval for personalized molecular residual disease (MRD) testing and establishes Natera's Treatment on MRD (TOMR) approach as a new standard of care. The approval is based on the IMvigor011 trial, which showed significant improvements in disease-free and overall survival for MRD-positive patients treated with immunotherapy.
(NTRA) Movement as an Input in Quant Signal Sets
This article analyzes Natera Inc. (NASDAQ: NTRA) using AI-generated quantitative signals, highlighting a weak near-term sentiment but strong long-term outlook. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside a multi-timeframe signal analysis indicating varying support and resistance levels. The analysis identifies an exceptional 59.6:1 risk-reward setup targeting a 17.1% gain.
Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock
Cathie Wood's ARK Invest has continued to rebalance its biotech portfolio, selling shares in Twist Bioscience, CareDx, and Adaptive Biotechnologies. Concurrently, ARK significantly increased its stake in Natera, acquiring over 17,000 shares across its ARKK and ARKG ETFs. These actions demonstrate a strategic shift within the biotech sector, focusing on growth opportunities in Natera while reducing exposure to other holdings.
Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Earnings: Here's What Analysts Think
This article provides an analysis of Natera, Inc.'s first-quarter earnings, highlighting key financial outcomes such as revenue and earnings per share. It also presents the updated outlook and price targets from analysts following the earnings release. The report aims to give investors an understanding of Natera's recent performance and future expectations as perceived by financial experts.
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report
Natera, Inc. recently reported mixed first-quarter results, with revenues beating expectations but statutory losses being larger than forecast. Analysts have since updated their 2026 forecasts, upgrading revenue and loss per share estimates, though the price target remains largely unchanged. Despite anticipated slower revenue growth compared to its industry peers, the overall sentiment shows a moderate uplift.
Natera, Inc. Stock 12‑Month Price Target Raised to $260.5, Implies 19% Upside
Eighteen analysts have raised Natera, Inc.'s average 12-month price target from $258 to $260.78, with a range of $190 to $300 per share. This new target suggests a potential upside of approximately 19% from its May 7 closing price. The consensus rating for NTRA remains a "Buy" from 20 covering analysts, with 18 recommending "Buy" and 2 recommending "Hold".
Why Natera (NTRA) Is Down 5.9% After Raising 2026 Guidance But Posting a Wider Q1 Loss
Natera (NTRA) saw its stock drop by 5.9% despite raising its 2026 revenue and gross margin guidance after its Q1 2026 earnings report. While the company achieved record testing volumes and revenue growth to US$696.64 million, its net loss widened to US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion. This outcome highlights the ongoing tension for Natera between strong growth and the challenge of achieving profitability amidst significant investment.
Number of shareholders of Natera, Inc. – BX:NTRA
This article displays a page dedicated to the number of shareholders of Natera, Inc. (BX:NTRA) on TradingView. It provides market information and financial data for the company. The page appears to be a historical data view, as specific shareholder numbers are not provided in the snippet, only a "Period Value Change Change %" section.
Earnings call transcript: Natera Inc. sees mixed Q1 2026 results; stock drops
Natera Inc. (NTRA) reported mixed Q1 2026 results, with revenue of $696.64 million significantly exceeding forecasts but an EPS of -$0.60 missing expectations. The stock dropped 9.69% in after-hours trading. The company highlighted strong revenue growth, improved gross margins, and promising adoption rates for new products like Fetal Focus, while also raising its full-year gross margin guidance.
Natera Lifts 2026 Outlook As Test Volumes Climb And Japan Entry Nears
Natera (NTRA) has raised its full-year 2026 revenue and gross margin guidance due to record test volumes and accelerating growth in women's health and oncology. The company also announced plans to launch its Signatera MRD test in Japan, aiming for international expansion. Despite a Q1 net loss of US$85.09 million, the increased guidance reflects management's confidence in future volumes, pricing, and product mix, balanced against ongoing investment in R&D and market expansion.
Natera Stock To $136?
Natera (NTRA) stock has dropped 11.6% recently and Trefis analysts believe it could fall further, possibly to $136, due to its very high valuation. Historically, sharp dips in NTRA (20% or more within 30 days) have been followed by a median 12-month return of 41%, with peak returns reaching 81%; however, timing these dips is challenging, and the article suggests staying invested through diversification. The company passes basic financial quality checks such as revenue growth and cash flow.
Natera, Inc. Stock 12‑Month Price Target Raised to $260.78, Implies 19% Upside
The average 12-month price target for Natera, Inc. (NTRA) stock has been raised to $260.78 by 18 analysts, up from $258. This new target suggests a potential upside of approximately 19% from its May 7 closing price. The consensus rating for NTRA remains a "Buy" among 20 analysts.
Natera’s Earnings Call Signals Strong Growth Momentum
Natera Inc. (NTRA) reported a strong Q1 earnings call, highlighting significant growth in revenue, volumes, and pricing across its oncology and women's health segments. The company processed a record 1 million units, saw a 55% year-over-year increase in oncology tests, and raised its full-year revenue outlook by over $120 million. Despite short-term headwinds like temporary cash collection delays and acquisition-related costs, Natera's management expressed confidence in sustained growth, driven by strategic integrations, assay enhancements, and emerging markets like Japan.
CCORF Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $285
CCORF has reiterated its Buy rating for Natera (NTRA.US) and maintained its target price at $285. This indicates a continued positive outlook from the analyst firm regarding Natera's stock performance.
Natera (NTRA) Q4 Profit Of US$47.3 Million Tests Longstanding Loss‑Making Narrative
Natera (NTRA) reported a Q4 2025 profit of US$47.3 million, marking a significant shift from previous losses and surprising many given its long-standing loss-making narrative. While the company still shows sizeable trailing twelve-month losses, the Q4 profit and increased revenue are seen by bulls as an early sign that growth investments are starting to generate returns. However, the stock's valuation, trading at 13.6x P/S, remains a point of contention for skeptics.
Natera: Q1 Earnings Snapshot
Natera Inc. (NTRA) reported a first-quarter loss of $85.1 million, or 60 cents per share, which missed Wall Street expectations. The genetic testing company, however, exceeded revenue forecasts, posting $696.6 million for the period. Natera anticipates full-year revenue to be between $2.74 billion and $2.82 billion.
Natera, Inc. Stock 12‑Month Price Target Raised to $260.22, Implies 18% Upside
Analysts have increased the average 12-month price target for Natera, Inc. (NTRA) stock to $260.78, up from $258, reflecting an approximate 19% potential upside from the May 7 closing price. The consensus rating for NTRA remains a "Buy" among 20 analysts, with 18 recommending a Buy and 2 a Hold. Investors can find more detailed analyst data and track recommendations on TradingView.
Natera, Inc. (NASDAQ:NTRA) Q1 2026 Earnings Call Transcript
Natera, Inc. reported strong first-quarter 2026 results with $697 million in revenue, a 39% year-over-year increase, driven by rapid growth in women's health and record oncology volumes. The company's Fetal Focus product launch is exceeding expectations, and its Signatera MRD test is gaining significant traction, including data supporting surgery avoidance in certain cancer patients. Natera has also raised its full-year revenue guidance by over $120 million and increased its gross margin guidance to 65%, while expecting a significant market expansion with its upcoming Japan launch and early cancer detection initiatives.
Natera Reports First Quarter 2026 Financial Results
Natera, Inc. announced strong financial results for the first quarter of 2026, with total revenues increasing by 38.8% to $696.6 million and processing over one million tests for the first time. The company reported a gross margin of 64.7% and achieved positive cash inflow of $11.8 million. Natera also raised its 2026 annual revenue guidance to $2.74 billion - $2.82 billion, driven by increased adoption of its Signatera and Fetal Focus products.
NTRA SEC Filings - Natera Inc 10-K, 10-Q, 8-K Forms
This article provides an overview of Natera Inc.'s (NTRA) SEC filings, including 10-K, 10-Q, and 8-K forms, detailing regulatory records for the Nasdaq-listed diagnostics company. It highlights recent insider trading activities, specifically sales by Executive Chairman Matthew Rabinowitz's spouse, co-founder Jonathan Sheena, and Daniel Rabinowitz, all reported through Form 4 and Form 144 filings with AI-generated summaries and sentiment analysis. The platform, StockTitan, tracks 210 SEC filings for Natera and offers tools like impact scoring and sentiment analysis for each disclosure.
Natera (NTRA) grows Q1 2026 revenue to $696.6M while net loss widens
Natera, Inc. (NTRA) reported a significant increase in total revenues to $696.6 million in Q1 2026, up from $501.8 million in the prior-year quarter, primarily driven by product revenues. Despite this robust top-line growth, the company's net loss widened to $85.1 million from $66.9 million, as research and development and selling, general, and administrative expenses also expanded substantially. The company maintains a strong liquidity position with $1.09 billion in cash and equivalents, underscoring its continued investment in product development and commercialization efforts.
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Natera (NTRA) reported Q1 2026 revenue of $696.64 million, a 38.8% increase year-over-year, exceeding the Zacks Consensus Estimate by 13.26%. Despite this, the EPS came in at -$0.56, missing the consensus estimate of -$0.53. Key metrics like tests processed and product revenues surpassed analyst expectations, though the stock's recent performance lagged the broader market.
Natera (NTRA) lifts 2026 outlook after 39% Q1 revenue surge
Natera reported a strong first quarter in 2026 with revenue surging 38.8% to $696.6 million, driven by increased test volumes across oncology and women's health. While the company still posted an increased net loss of $85.1 million due to higher operating expenses, it raised its full-year 2026 revenue guidance to $2.74–$2.82 billion and expects positive net cash inflow. This positive outlook is supported by record test volumes and significant momentum in its Signatera minimal residual disease test.
Natera tops 1 million tests in a quarter, raises 2026 forecast
Natera, Inc. reported strong first-quarter 2026 financial results, with total revenues increasing by 38.8% to $696.6 million and reaching a milestone of over 1 million tests processed. The company raised its 2026 annual revenue guidance to $2.74 billion - $2.82 billion, driven by significant growth in both Women’s Health and Oncology segments. Natera continues to focus on expanding its cell-free DNA and genetic testing services to transform patient care.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) reported a Q1 loss of $0.56 per share, slightly wider than the Zacks Consensus Estimate of a $0.53 loss. However, the genetic testing company surpassed revenue estimates with $696.64 million for the quarter, largely exceeding the Zacks Consensus Estimate by 13.26% and prior-year revenues. Despite underperforming the S&P 500 year-to-date, Natera holds a Zacks Rank #3 (Hold) based on mixed estimate revisions.
Natera executive chairman sells $1.64m in shares
Matthew Rabinowitz, Executive Chairman of Natera, Inc. (NASDAQ:NTRA), sold approximately $1.64 million in shares, primarily to cover tax obligations from vesting Restricted Stock Units (RSUs). These transactions occurred on May 4 and May 5, 2026, and were executed under Rule 10b5-1 trading plans. Rabinowitz also received 2,389 fully-vested RSUs, and now directly holds over 2.3 million Natera shares.
Natera (NTRA) chair sells shares for RSU taxes, receives grant
Matthew Rabinowitz, Executive Chairman of Natera (NTRA), sold 7,708 shares of common stock in open-market transactions to cover tax obligations related to the vesting of 2,389 Restricted Stock Units (RSUs) he received. The sales were conducted under a Rule 10b5-1(c) plan, indicating they were pre-arranged. Following these transactions, Rabinowitz directly holds 2,378,791 common shares, with an additional 5,000 shares held indirectly by his spouse.
Natera (NTRA) CEO sells 902 shares in RSU-related tax transaction
Natera CEO Steven Leonard Chapman sold 902 shares of common stock on May 1, 2026, at $206.16 per share. This transaction was conducted to cover tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) and was pre-arranged under a Rule 10b5-1(c) plan. Following the sale, Chapman directly owns 149,867 shares of Natera common stock.
Natera co-founder Sheena Jonathan sells $22,059 in common stock
Sheena Jonathan, co-founder of Natera, Inc., sold 107 shares of company stock for $22,059 to cover tax obligations from vested restricted stock units. The transaction was pre-arranged, and she continues to hold significant direct and indirect shares. This news follows other positive developments for Natera, including an "Outperform" rating from William Blair, a patent victory, a new board appointment, and promising scientific results for its Signatera assay.
Natera CEO Steven Chapman disposes of $185,956 in company stock
Steven Leonard Chapman, CEO of Natera, Inc. (NASDAQ:NTRA), sold 902 shares of company stock for $185,956 on May 1, 2026, to cover tax obligations related to restricted stock unit vesting. Following the sale, Chapman still directly owns 149,867 shares. This transaction follows other recent positive developments for Natera, including a favorable court decision, a new board member, and promising study results for its Signatera assay.
Natera president John Fesko sells $59,992 of NTRA shares
Natera's President and Chief Business Officer, John Fesko, sold 291 shares of NTRA stock worth $59,992 on May 1, 2026, to cover tax obligations from restricted stock unit vesting. This transaction, made under a Rule 10b5-1 plan, leaves Fesko with 187,220 shares. The sale occurred ahead of Natera's earnings report, with the stock down 9.74% year-to-date.
